Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 28-34

  Yang, Zhijun ^a   Luo, Zhaoqin ^a   Zhao, Bingbing ^a   Zhang, Wei ^a   Zhang, Jieqing ^a   Li, Zhuang ^a   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

CA125; Debulking; Diagnosis; HE4; Ovarian neoplasm

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CHEMILUMINESCENCE IMMUNOASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GREATER OMENTUM; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SENSITIVITY AND SPECIFICITY;

EID: 84878309059     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1339     Document Type: Article

References (19)

1. Shaaban A and Rezvani M: Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol 52: 73-93, 2009.
2. Chen WQ, Zhang SW and Zou XN: Cancer incidence and mortality in China, 2006. Chin J Cancer Res 23: 3-9, 2011 (In Chinese).
3. Nolen BM and Lokshin AE: Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol 8: 55-71, 2012.
4. Li J, Dowdy S, Tipton T, et al: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9: 555-566, 2009.
5. Kirchhoff C, Habben I, Ivell R and Krull N: A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45: 350-357, 1991.
6. Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod 3: 86-95, 1998.
7. Galgano MT, Hampton GM and Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19: 847-853, 2006.
8. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO and Bast RC Jr: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402-408, 2008.
9. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB and Huntsman D: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232, 2008.
10. Deraco M, Baratti D, Laterza B, et al: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37: 4-9, 2011.
11. Chua TC, Liauw W, Robertson G and Morris DL: Second-line treatment of first relapse recurrent ovarian cancer. Aust N Z J Obstet Gynaecol 50: 465-471, 2010.
12. Berry NB, Cho YM, Harrington MA, Williams SD, Foley J and Nephew KP: Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 92: 896-904, 2004.
13. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr and Skates SJ: A noval multiple marker bioassay utiliazing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40-46, 2009.
14. Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L and Mulligan J: Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229: 101-108, 1999.
15. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous andendometrioid ovarian carcinomas. Cancer Res 65: 2162-2169, 2005.
16. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M and Guidi GC: The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23: 331-335, 2009.
17. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr and Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117: 440-445, 2010.
18. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P and Urban N: Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 116: 378-383, 2010.
19. Xu CL, Yang YH and Wang HL: The value of serum human epididymis protein 4 epithelial in the diagnosis of ovarian cancer. Chinese Journal of Gynecology and Obstetrics 26: 684-686, 2010.